Takeda Pharmaceutical Company Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. It's just about 5:00 P.M., so I think we can get started. Thanks very much for joining this session. My name's Steve Barker. I cover Japanese healthcare for Jefferies in Japan, and it's my pleasure to be hosting this session with Takeda Pharmaceutical Company. We have the CEO, Julie Kim. We have Andy Plump, Head of R&D, and we also have Milano Furuno, CFO. Everybody, thanks very much for joining us. I'd like to jump straight in with a question for you, Julie.
Sure. I think a lot of companies would be excited to even have one blockbuster, something as interesting as ORZEYFUL for your narcolepsy type 1 program, but you actually have three very exciting blockbusters coming out.
Yes. You also have MIMRYLO for polycythemia vera, and then very soon, you're very likely to get approval for zasocitinib for psoriasis.
How are you preparing to give these three opportunities the attention they deserve?
Yeah. Look, we've already launched two of them, and so I would say this. From a total company perspective, we're making sure that we have the right level of resources dedicated to each of these launch assets, and happy to say that both for MIMRYLO and ORZEYFUL that have launched, they are doing really well. Very pleased about their performance to date, and as you said, we're waiting for zasocitinib. We do have priority review with the FDA, and we expect to have an answer in March.
Okay, that's great. Andy, I have a question for you around zasocitinib. It's been encouraging to see that there clearly is demand for oral treatments for psoriasis. We've seen that in the market. Do you think dermatologists are ready to embrace alternatives to the injectables?
Well, maybe I'll start, Julie, and I'll hand it over to you and just talk a little bit about the profile of zasocitinib in psoriasis. When we brought this compound in over four years ago, we were excited about the data that we had seen, and every data set that we've revealed since then has just made us even more excited. We actually just had head-to-head data with deucravacitinib, so it's not really kind of a poised competition for us, but it's a benchmark, and it suggests the level of efficacy that we have. It's very unusual to go head-to-head against another member in the same class. We did that on our primary endpoint, which was 100% skin clearance. We had a 2.5 times greater effect.
We saw, just by point estimate, the most significant effects on this endpoint, PASI 100, in any psoriasis trial at week 16, which is about 36%.
Yeah, when you look at the oral segment today, and if we just focus on the U.S. market for a moment, the oral segment today represents roughly 10% of the overall, and we do believe that there's significant room for that segment to grow. J&J, as you know, has launched last year into this space with an effective oral. We do believe that there's room for more than one oral, and we like zasocitinib's profile. So, in addition to the great data that Andy mentioned, we don't have a food restriction for zasocitinib. zasocitinib works very well across all patient types within psoriasis, and we have fast onset of activity, of efficacy, strong durability. There's nothing that we are worried about when it comes to zasocitinib, so we're looking forward to the eventual approval and another launch.
Very effective data, as you mentioned, Andy. Where do you see the opportunity with the patients? Is it patients who do not want to have injections for some reason, or where is the opportunity?
Yeah. When you look at the progression of patients onto therapy. First, going onto an injectable is quite a scary thing, but if you have really severe disease, you probably will. Most would like to try an oral first, but the existing oral previously was not that effective across patient types. Now they have had an effective oral for one year, and we have seen the pickup of that. So again, zasocitinib, as another really effective oral agent, the profile that it has, we think it will do well.
Right. Milano, I have a question for you. Three major launches. It is a nice problem to have, but it does require substantial investment upfront. I know you have a cost-saving program underway. Could you tell us something about that? How are you funding the investment that these launches require?
Yeah. This year, we are already increasing commercial investments. We are planning to invest almost like JPY 100 billion. It is almost the same amount, JPY 100 billion for the commercial investments. Perhaps it is highly likely we increase a little bit more for next year, because it is going to be the first full year launching those three products. In the meantime, we are running the transformation program, the cost savings program, with combining more like strategic organizational change program. We are making Basically, the big change in organizationally, we are delayering some management layers, we are centralizing some corporate functions, we are leveraging some global capability centers. So the making more efficient organization, process standardization, and then getting the savings to fund all those commercial launches. So that is how we are managing the incremental cost investments by the cost savings program.
Right. JPY 100 billion investment this year, going up a little bit next year.
Yeah. You have the ongoing savings program.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
